MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.82
-0.75
-2.17%
After Hours: 33.82 0 0.00% 16:37 09/20 EDT
OPEN
33.90
PREV CLOSE
34.57
HIGH
34.63
LOW
33.36
VOLUME
205.15K
TURNOVER
--
52 WEEK HIGH
58.35
52 WEEK LOW
30.12
MARKET CAP
1.97B
P/E (TTM)
92.38
1D
5D
1M
3M
1Y
5Y
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
MONROVIA, Calif., September 20, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company managem...
Business Wire · 6h ago
INmune Bio Shares Plunge as Xencor Plans to Sell INmune Shares
MT Newswires · 09/08 15:43
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 11:35
Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
COMTEX_392115206/2669/2021-08-24T08:30:34
CNW Group · 08/24 12:30
Return on Capital Employed Insights for Xencor
After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total of $67.45 million in sales, a 98.58% increase since Q1.
Benzinga · 08/20 18:04
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
Benzinga · 08/17 10:37
--SVB Leerink Adjusts Xencor's Price Target to $53 from $57, Keeps Outperform Rating
MT Newswires · 08/05 12:25
--RBC Cuts Price Target on Xencor to $53 From $55, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires · 08/05 09:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XNCR. Analyze the recent business situations of Xencor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XNCR stock price target is 53.55 with a high estimate of 63.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 239
Institutional Holdings: 62.73M
% Owned: 107.56%
Shares Outstanding: 58.32M
TypeInstitutionsShares
Increased
62
1.62M
New
23
328.91K
Decreased
65
1.61M
Sold Out
15
864.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
President/Chief Executive Officer/Founder/Director
Bassil Dahiyat
Chief Financial Officer/Senior Vice President
John Kuch
Senior Vice President/Chief Scientific Officer
John Desjarlais
Senior Vice President
Allen Yang
Vice President/General Counsel/Secretary
Celia Eckert
Vice President
Jeremy Grunstein
Vice President
Eric Kowack
Vice President
Kirk Rosemark
Other
Julie Casciani
Lead Director/Independent Director
A. Bruce Montgomery
Independent Director
Ellen Feigal
Independent Director
Kevin Gorman
Independent Director
Kurt Gustafson
Independent Director
Yujiro Hata
Independent Director
Richard Ranieri
Independent Director
Dagmar Rosa - Bjorkeson
No Data
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.